Bolt Biotherapeutics has filed a patent for immunoconjugates that consist of a cell-binding agent linked to immunostimulatory moieties through a peptide linker unit that is a substrate for elastase. The patent also covers intermediate compositions that can be used to form the immunoconjugates. The invention aims to provide methods for treating cancer using these immunoconjugates. GlobalData’s report on Bolt Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bolt Biotherapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Bolt Biotherapeutics's grant share as of September 2023 was 6%. Grant share is based on the ratio of number of grants to total number of patents.
Immunoconjugates for cancer treatment using elastase-substrate peptide linker
A recently filed patent (Publication Number: US20230293716A1) describes an immunoconjugate that consists of a cell-binding agent covalently attached to one or more immunostimulatory moieties by a linker comprising an elastase-substrate, peptide linker unit. The cell-binding agent is an antibody construct that binds to specific targets such as PD-L1, HER2, CEA, and TROP2. The patent also mentions specific antibodies that can be used, including atezolizumab, durvalumab, avelumab, trastuzumab, pertuzumab, labetuzumab, and sacituzumab, or their biosimilars or biobetters. The immunoconjugate can also include immunostimulatory moieties that interact with or modulate receptors such as TLR, STING, NOD2, RIG-1, and NLRP3. The patent provides a specific formula for the immunoconjugate and its various components, including the elastase-substrate, peptide linker unit and the immunostimulatory moieties. The patent also describes the use of the immunoconjugate in pharmaceutical compositions for the treatment of immune-related disorders and cancer, particularly cancers that express PD-L1, HER2, CEA, or TROP2 and are susceptible to a pro-inflammatory response induced by TLR7 and/or TLR8 agonism, or by STING agonism. The patent further mentions methods of treatment using the pharmaceutical composition, including the administration of the immunoconjugate to patients with bladder cancer, urinary tract cancer, urothelial carcinoma, lung cancer, non-small cell lung cancer, Merkel cell carcinoma, colon cancer, colorectal cancer, gastric cancer, and breast cancer. Overall, the patent describes a novel immunoconjugate and its potential applications in the field of immunotherapy for the treatment of various diseases, particularly cancer.
To know more about GlobalData’s detailed insights on Bolt Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
